Pan-PI3K inhibitors, such as buparlisib and pictilisib (inhibiting p110α/β/γ/δ); PI3K isoform-specific inhibitors such as alpelisib and taselisib (inhibiting p110α and p110α/γ/δ, respectively); AKT inhibitors such as ipatasertib, capivasertib (AZD5363), and vevorisertib (MK-2206); PI3K/AKT dual inhibitor gedatolisib (PF-05212384); and mTOR inhibitors such as everolimus, vistusertib, and sapanisertib are currently available for the treatment of BC (243). This evidence concerns the gene PIK3CA and breast cancer.